ClinicalTrials.gg
CompletedNCT03374241Updated Feb 6, 2025Results posted

A First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM15211(Efocipegtrutide)

A Phase 1 interventional study of HM15211 or Placebo in Obesity, sponsored by Hanmi Pharmaceutical Company Limited. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-02-06.

Sponsored by Hanmi Pharmaceutical Company Limited · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
41
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

Single ascending dose of HM15211 in healthy obese subjects.

Read the detailed description

A First-in-human study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics after single ascending dose of HM15211 in healthy obese subjects.

02

Conditions studied

  • Obesity

Browse trials for

03

In context

Obesity

11,536 studies on the registry are indexed under Obesity; 2,055 are open to participants now.

This study's enrollment of 41 is below the median of 67 across 9,036 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Hanmi Pharmaceutical Company Limited is the lead sponsor of 191 studies on the registry; 12 are open to participants now.

Of its 11 completed or terminated interventional studies of FDA-regulated products, 6 (55%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female subjects must be non-pregnant and non-lactating

Exclusion criteria

Exclusion Criteria:

  • Participation in an study within 30 days prior to dosing
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
41 participants (actual)

Study arms

  • Experimental
    Cohort 1

    HM15211 or Placebo (single dose, subcutaneous injection)

    Biological: HM15211 or Placebo

  • Experimental
    Cohort 2

    HM15211 or Placebo (single dose, subcutaneous injection)

    Biological: HM15211 or Placebo

  • Experimental
    Cohort 3

    HM15211 or Placebo (single dose, subcutaneous injection)

    Biological: HM15211 or Placebo

  • Experimental
    Cohort 4

    HM15211 or Placebo (single dose, subcutaneous injection)

    Biological: HM15211 or Placebo

  • Experimental
    Cohort 5

    HM15211 or Placebo (single dose, subcutaneous injection)

    Biological: HM15211 or Placebo

Interventions

  • BiologicalHM15211 or Placebo

    Long-acting tri-agonist

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events

    An adverse event is any undesirable and unintended medical event occurring to a subject in a clinical study, whether or not related to the investigational products

    Time frame: 1 month

07

Results

Posted May 17, 2024

Participant flow

Participant flow — Overall Study
MilestoneCohort 1Cohort 2Cohort 3Cohort 4Cohort 5Placebo
Started6667610
Completed6655510
Not completed001210

Outcome measures

PrimaryNumber of Participants With Adverse Events

An adverse event is any undesirable and unintended medical event occurring to a subject in a clinical study, whether or not related to the investigational products

Time frame:
1 month
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events
ParticipantsCohort 1 ActiveCohort 2 ActiveCohort 3 ActiveCohort 4 ActiveCohort 5 ActivePlacebo
Number of Participants With Adverse Events323747

Adverse events

Collected over 1 month. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1 Active0/6 (0%)0/6 (0%)3/6 (50%)
Cohort 2 Active0/6 (0%)0/6 (0%)2/6 (33.3%)
Cohort 3 Active0/6 (0%)0/6 (0%)3/6 (50%)
Cohort 4 Active0/7 (0%)0/7 (0%)7/7 (100%)
Cohort 5 Active0/6 (0%)0/6 (0%)4/6 (66.7%)
Placebo0/10 (0%)0/10 (0%)7/10 (70%)
Most frequent other events
Showing 10 of 11
Most frequent other events
EventCohort 1 ActiveCohort 2 ActiveCohort 3 ActiveCohort 4 ActiveCohort 5 ActivePlacebo
GI disordersGastrointestinal disorders0/60/61/64/74/61/10
Nervous system disordersNervous system disorders0/61/60/64/72/62/10
General disorders and administrationGeneral disorders2/61/61/62/71/64/10
Infections and infestationsInfections and infestations1/60/60/60/72/60/10
Musculoskeletal and connective tissueMusculoskeletal and connective tissue disorders1/60/62/60/71/60/10
Blood and lymphatic system disordersBlood and lymphatic system disorders0/61/60/60/71/60/10
Eye disordersEye disorders0/60/61/60/70/60/10
Renal and urinary disordersRenal and urinary disorders0/60/60/60/71/60/10
Respiratory, thoracic and mediastinalRespiratory, thoracic and mediastinal disorders1/60/60/60/70/60/10
Metabolism and nutrition disordersMetabolism and nutrition disorders0/60/60/61/70/60/10

Baseline characteristics

all randomized subjects (total 41)

Age, Categorical
Age, Categorical(Participants)Cohort 1 ActiveCohort 2 ActiveCohort 3 ActiveCohort 4 ActiveCohort 5 ActivePlaceboTotal
<=18 years0000000
Between 18 and 65 years666761041
>=65 years0000000
Age, Continuous
Age, Continuous(years)Cohort 1 ActiveCohort 2 ActiveCohort 3 ActiveCohort 4 ActiveCohort 5 ActivePlaceboTotal
Mean41.0 ± 14.3436.3 ± 11.7854.0 ± 6.1349.7 ± 11.0643.8 ± 13.5347.4 ± 6.5545.7 ± 11.38
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1 ActiveCohort 2 ActiveCohort 3 ActiveCohort 4 ActiveCohort 5 ActivePlaceboTotal
Female34242520
Male32434521
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cohort 1 ActiveCohort 2 ActiveCohort 3 ActiveCohort 4 ActiveCohort 5 ActivePlaceboTotal
Hispanic or Latino15134418
Not Hispanic or Latino51542623
Unknown or Not Reported0000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort 1 ActiveCohort 2 ActiveCohort 3 ActiveCohort 4 ActiveCohort 5 ActivePlaceboTotal
American Indian or Alaska Native0000000
Asian0000011
Native Hawaiian or Other Pacific Islander0001001
Black or African American21410412
White45256527
More than one race0000000
Unknown or Not Reported0000000
Region of Enrollment
Region of Enrollment(participants)Cohort 1 ActiveCohort 2 ActiveCohort 3 ActiveCohort 4 ActiveCohort 5 ActivePlaceboTotal
United States666761041
08

Study locations

1 site
  • Hanmi Investigative Site
    Chula Vista, California 91911, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2018 to primary completion in Sep 2018, 5 months.

Results were first posted in May 2024, 5 years 8 months after primary completion.

Of 338 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 5 months is below that.

Counting every sponsor, half of 443 studies reached it within 11 months; a quarter within 6 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 12, 2017
First posted
Dec 15, 2017
StartActual
Apr 4, 2018
Primary completionActual
Sep 14, 2018
CompletionActual
Sep 14, 2018
Results first posted
May 17, 2024
Last update
Feb 6, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 6, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03374241
Responsible party
Sponsor
First posted
Dec 15, 2017
Start date
Apr 4, 2018
Primary completion
Sep 14, 2018
Completion
Sep 14, 2018
Results posted
May 17, 2024
Last update
Feb 6, 2025

Study contacts

Hanmi Pharmaceuticals
study director · Hanmi Pharmaceuticals

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion